ReviewClinical infectious diseases : an official publication of the Infectious Diseases Society of America2026
The Role of β-Lactam Antibiotics in Treating Mycobacterium abscessus: From Laboratory Insights to Clinical Applications and the Case for Clinical Trials.
Review in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Pharmacokinetics and Physiologically Based Pharmacokinetic Modeling of Mycobacteriophages: Insights into Pulmonary Distribution and Clearance.Molecular pharmaceutics · 2026Article
- Article
- Response to "The promise and pitfalls: interpreting dual β-lactam success inASM case reports · 2026Article
- A Year in Review on Tuberculosis and Non-tuberculous Mycobacteria Disease: A 2026 Update for Clinicians and Scientists.Pathogens & immunity · 2026Review
- Loss-of-Function Mutations in the Penicillin-Binding Protein PonA1 Confer Agar-Dependent Resistance to Durlobactam inAntibiotics (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mycobacterium abscessus (Mab) is a highly drug-resistant non-tuberculous mycobacterium that presents major treatment challenges, particularly in individuals with structural lung disease. Although historically considered ineffective, β-lactam antibiotics have gained renewed attention due to advances in β-lactamase inhibition and cell wall biology. This review synthesizes more than a decade of work, including in vitro susceptibility studies, biochemical characterization of Mab's β-lactamase (BlaMab) and peptidoglycans synthesis, and published clinical cases supporting the potential role of β-lactam-based regimens. We detail the enzymatic pathways involved in peptidoglycan cross-linking and the dual inhibition of D,D- and L,D-transpeptidases by select β-lactams, as well as the functional impact of inhibiting BlaMab. Novel β-lactamase inhibitors such as durlobactam may further enhance β-lactam efficacy. By integrating laboratory insights with clinical experience, this review provides a comprehensive perspective and informs ongoing efforts to design clinical trials repurposing β-lactam/β-lactamase inhibitor combinations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.